PriceTargets.com logo

LENSAR - LNSR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 3.90%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.70 As of 12/20/2024 06:16 PM ET
▲ +0.2 (2.67%)

This chart shows the closing price for LNSR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LENSAR Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LNSR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LNSR

Analyst Price Target is $8.00
▲ +3.90% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for LENSAR in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 3.90% upside from the last price of $7.70.

This chart shows the closing price for LNSR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in LENSAR.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/19/2024Lake Street CapitalInitiated CoverageBuy$8.00
7/17/2023BTIG ResearchLower Target$12.00 ➝ $8.00
8/15/2022BTIG ResearchLower Target$14.00
11/22/2021BTIG ResearchInitiated CoverageBuy$15.00
10/22/2021Leerink PartnersReiterated RatingOutperform
2/24/2021Leerink PartnersInitiated CoverageOutperform$20.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
LENSAR logo
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Read More

Today's Range

Now: $7.70
Low: $7.35
High: $7.88

50 Day Range

MA: $6.78
Low: $5.17
High: $7.89

52 Week Range

Now: $7.70
Low: $2.63
High: $8.17

Volume

42,596 shs

Average Volume

34,649 shs

Market Capitalization

$89.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of LENSAR?

The following Wall Street sell-side analysts have issued reports on LENSAR in the last year: Lake Street Capital.
View the latest analyst ratings for LNSR.

What is the current price target for LENSAR?

0 Wall Street analysts have set twelve-month price targets for LENSAR in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 3.9%. Lake Street Capital has the highest price target set, predicting LNSR will reach $8.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $8.00 for LENSAR in the next year.
View the latest price targets for LNSR.

What is the current consensus analyst rating for LENSAR?

LENSAR currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LNSR will outperform the market and that investors should add to their positions of LENSAR.
View the latest ratings for LNSR.

What other companies compete with LENSAR?

Other companies that are similar to LENSAR include AVITA Medical, CVRx, Sanara MedTech, Zynex and Pulmonx. Learn More about companies similar to LENSAR.

How do I contact LENSAR's investor relations team?

The company's listed phone number is 888-536-7271 and its investor relations email address is [email protected]. The official website for LENSAR is www.lensar.com. Learn More about contacing LENSAR investor relations.